MNMD - Mind Medicine (MindMed) Inc.
About Mind Medicine (MindMed) Inc. (https://www.mindmed.co)
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Robert Barrow | Chief Executive Officer & Director | 1989 | $997,010 USD |
| Daniel Rollings Karlin | Chief Medical Officer | 1980 | $703,319 USD |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | 1971 | $638,607 USD |
| Brandi L. Roberts | Chief Financial Officer | 1974 | $608,624 USD |
| Scott Freeman | Co-Founder & Clinical Advisor | 1957 | $309,621 USD |
| Beth Calitri | Vice President of Corporate Communications | – | – |
| Gregg Pratt | Chief Regulatory & Quality Assurance Officer | – | – |
| Leonard Latchman | Co-founder | – | – |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | – | – |
| Stephanie Fagan | Chief Corporate Affairs Officer | – | – |